PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
30.26%
Net income growth 1.25-1.5x TRVN's 24.76%. Bruce Berkowitz would verify whether cost discipline or revenue gains drive the outperformance.
-2.10%
Both reduce yoy D&A, with TRVN at -2.24%. Martin Whitman would suspect a lull in expansions or intangible additions for both.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Negative yoy SBC while TRVN is 19.40%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-263.50%
Both reduce yoy usage, with TRVN at -212.61%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-14.17%
Both reduce yoy usage, with TRVN at -130.44%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-397.71%
Negative yoy while TRVN is 417.91%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
10.50%
Some CFO growth while TRVN is negative at -10.45%. John Neff would note a short-term liquidity lead over the competitor.
-802.66%
Negative yoy CapEx while TRVN is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.56%
We cut debt repayment yoy while TRVN is 0.06%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
-100.00%
Negative yoy issuance while TRVN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.